Preclinical murine models of melanoma suggest that PTEN loss promotes resistance to T cell-mediated immunotherapy by decreasing T cell trafficking into the tumours.4 Moreover, trials of PI3Kbeta inhibitor in this model improved the efficacy of both anti-PD-1 and anti-CTLA-4 antibodies. The gene discussed is CTLA4; the disease is melanoma.